baber/WOPTO huggingface dataset:
Patent NZ-331889-A (NZ)
Title: Trypanosomatids histones for use as an antigen against trypanosomatic infection, including diagnostic tests, pharmaceutical compositions and vaccines of these antigens
Inventor: FASEL NICOLAS JOSEPH
IPC: C12Q1/68
Filed: 1997-03-12
Abstract: Trypanosomatid histones in substantially isolated form are used as a protective antigen against trypanosomatic infection. These histones may be either isolated from the corresponding parasite (Leishmania) or be produced by means of recombinant DNA techniques. For the latter purpose genes encoding histones and derivatives of the genes like other nucleic acids and gene products like peptides and proteins are disclosed. Diagnostic tests, pharmaceutical compositions and vaccines comprising the usual excipients and/or adjuvants and at least one histone, a histone encoding gene or a derivative thereof are disclosed.
Patent NZ-508791-A (NZ)
Title: Retroviral particles with deletions in E1 and E4 regions characterised by the sequence of interest being present in between two long repeat regions (LTR)
Inventor: YEH PATRICE
IPC: C12N15/861
Filed: 1999-05-18
Abstract: A composition comprises a retroviral vector and genetic elements  encoding for retroviral proteins  that  complement the  retroviral  vector to allow for the constitution  of  a retroviral  particle. The vector and genetic elements  being incorporated  into  one or several recombinant  adenoviruses defective  for  all  or  part of at  least  the  E1  and  E4 regions.    Preferably  the  genetic  elements  comprise   a nucleic  acid coding for a retroviral gag protein, a nucleic acid  coding for a retroviral pol protein and a nucleic acid coding  for  an envelope protein and the vector comprises  a nucleic   acid  comprising,  between  two  LTR  regions,   a retroviral  packaging sequence and a nucleic  acid  sequence of   interest.  The  compositions  can  be  used   for   the preparation of a product for transferring nucleic acid  into cells
Patent NZ-509018-A (NZ)
Title: Software verification and authentication
Inventor: BOND EUGENE THOMAS
IPC: G06F21/51
Filed: 1999-06-17
Abstract: A device for controlling electronic gaming machines comprises a single board computer (SBC) having a microprocessor, memory means, storage means and a ROM (Read Only Memory). The ROM includes: a loader program; verification program; an authentication program; and a presentation program. Additional Mass storage media in communication with the SBC store pre-verified and approved gaming software (program files) and related data files, each of which have a verification signature appended to them. Prior to usage of the gaming software, the program file software or data file is retrieved by the loader program and checked by the verification program, which compares the verification signature with a newly calculated verification signature. If the newly calculated signature matches the verification signature, the requested file is deemed to be intact (a validated image). The verification processes ensure that the file has been retrieved in its entirety and is free from corruption caused by storage media faults. If any corruption has occurred, the control device displays an error and the process is halted. After verification, all pending requests for authorization from authentication agents are processed by a queuing means. Each request includes a set of authentication instructions and a reply destination. After queuing, an authentication interpreter processes the validated image pursuant to the requester's instruction. The presentation program reports the resulting authentication identification to the requested destination, which either acknowledges or refuses authentication. If acknowledged, the image is used or executed. If refused, an error is displayed and the process is halted.
Patent NZ-515355-A (NZ)
Title: Cyclocarbamate derivatives as progesterone receptor modulators
Inventor: ZHANG PUWEN
IPC: A61K31/537
Filed: 2000-05-01
Abstract: A cyclocarbamate derivative or pharmaceutically acceptable salt thereof has the formula (I) wherein: R1 and R2 are independently H or optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic or CORA or NRBCORA or are fused together to form an optionally substituted 3 to 8 membered spirocyclic alkyl ring, spirocyclic alkenyl ring or heterocyclic ring containing one to three heteroatoms from the group selected from O, S and N; R3 is H, OH, NH2, or optionally alkyl, alkenyl or alkynyl or CORC; RA, RB and RC are as defined in the specification; R4 is H, halogen, CN, NO2, amino or optionally alkyl, alkynyl, alkynyl, aminoalkyl or alkoxy; R5 is a trisubstituted benzene ring containing the substituents X, Y and Z as defined in the specification or an optionally substituted five or six membered ring with 1,2, or 3 heteroatoms selected from O, S, SO, SO2 or NR6 and R6 is H or alkyl. The compounds are useful for inducing contraception or treating hormone-dependent neoplastic disease.
Patent NZ-516439-A (NZ)
Title: Novel genetic sequences encoding steroid and juvenile hormone receptor polypeptides and uses therefor
Inventor: HILL RONALD JOHNSTON
IPC: C12N5/071
Filed: 2000-06-30
Abstract: Isolated nucleic acid molecules encoding polypeptides comprising functional steroid hormone and juvenile hormone receptors, in particular isolated nucleic acid molecules which encode polypeptides comprising the Lucilia cuprina, Myzus persicae, and Bemisia tabaci ecdysone receptors and juvenile hormone receptors.  Functional recombinant steroid and juvenile hormone receptors and recombinant polypeptide subunits thereof and screening systems and methods of identifying insecticidally-active agents which are capable of agonising or antagonising insect receptor function, or which modify the affinity of said receptors for their cellular stimuli (e.g. insect steroids or juvenile hormones) or analogues thereof, or which act as insecticides by virtue of their ability to agonise or antagonise the activity of insect hormones.
Patent NZ-519608-A (NZ)
Title: Immunogenic compositions comprising NmC oligosaccharide and NmB outer membrane protein and additional proteins and protective antigens
Inventor: GIULIANI MARZIA MONICA
IPC: A61K39/116
Filed: 2000-11-29
Abstract: International patent application WO99/61053 discloses immunogenic compositions that comprise N.meningitidis serogroup C oligosaccharide conjugated to a carrier, in combination with N.meningitidis serogroup B outer membrane protein. These are disclosed in the present application in combination with further Neisserial proteins and/or protective antigens against other pathogenic organisms (e.g. Haemophilus influenzae, DTP, HBV, etc.).
Patent NZ-524988-A (NZ)
Title: A document categorisation system
Inventor: RASKUTTI BHAVANI
IPC: G06F17/30
Filed: 2001-09-25
Abstract: A document categorisation system (10) comprises either:- a) a clusterer module (12) for generating clusters of related electronic documents based on features extracted from the documents; a filter module (14) for generating a filter on the basis of the clusters to categorise further documents received by the system and optionally a trend analyser module (18); b) a clusterer module (12) for generating clusters of related electronic documents based on features extracted from the documents; an editor (16) or browsing and modifying the clusters and optionally a trend analyser module (18); c) an editor (16) for browsing and modifying clustered documents; a filter (14) module for generating a filter on the basis of features of the clusters to categorise further documents received by the system and optionally a trend analyser module (18); or d) a clusterer module (12) for generating clusters of documents by executing unsupervised learning on the documents; a filter module (14) for generating a filter to categorise received documents by executing supervised learning on the clusters and optionally an editor (16) for adjusting the clusters and/or a trend analyser module (18). The clusterer (12) processes electronic messages or other documents (20) and groups them into a set (22) of clusters (24) of related documents and then creates a description in the form of a set of keywords and key phrases for each cluster (24). The editor/browser (16) provides an interactive user interface that allows browsing through the clustered documents and to modify the clusters if so desired so that each cluster contains a coherent set of documents. The filter module (14) analyses clusters in order to categorise new documents. The trend analyser (18) analyses clusters over various time periods and compares different categorisations of the same document to determine coherent and useful classifications for these documents and determines novel clusters.
Patent NZ-529414-A (NZ)
Title: Methods and compositions for controlling pests with a beta-dione compound
Inventor: SPOONER-HART ROBERT NEIL
IPC: A01M29/12
Filed: 2002-05-08
Abstract: Use of a beta-dione compound of formula (I) for the preparation of a composition for controlling harmful, annoying or undesired pests is disclosed, wherein: A is (C=O)R1, (C=S)R1, OR2, SR2, (CR3NR4R5), (C(R3)2OR2, NR4R5, (C=N-R-4)R1, N=O, N(=O)2, NR4OR2 or SO4R2; B is H, C1-C10 alkyl, C2-C10 alkenyl, aryl or heteroaryl; X and Y are independently selected from oxygen, sulfur -N-R4; and Q completes a 5-8-member saturated or unsaturated carbocyclic or heterocyclic ring in which optionally one or more members comprise -C(=X)-; and R1-R5 are as defined in the specification, with the proviso that the compound of formula (I) is not used to control plants, microbes, helminths and nematodes.
Patent NZ-535748-A (NZ)
Title: Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
Inventor: SHIMOJO MASATO
IPC: A61K31/421
Filed: 2003-04-03
Abstract: Disclosed is the use of EP4 receptor antagonists of formula (I) as described in the specification for the treatment of IL-6 involved diseases consisting of alcoholic cirrhosis, amyloidosis, artherosclerosis, cardiac disease, sclerosis and organ transplantation reactions. Also disclosed is the use of EP4 receptor ligands in the treatment of artherosclerosis.
Patent NZ-539870-A (NZ)
Title: Sustained-release solid dosage tramadol formulations with 24-hour efficacy
Inventor: LENAERTS VINCENT
IPC: A61K9/00
Filed: 2003-10-27
Abstract: Disclosed is a solid dosage formulation comprising: a core comprising at least one active pharmaceutical ingredient (API) and a matrix; and a coat comprising a physical mixture of polyvinyl acetate and polyvinylpyrrolidone and at least one active pharmaceutical ingredient, wherein at least one active pharmaceutical ingredient and the matrix of the core are associated in such a way that release of the pharmaceutical ingredient from the matrix of the core is controlled, so that release from the formulation of an active ingredient located in the core is slower than the release of the active pharmaceutical ingredient located in the matrix of the coat. The disclosure particularly relates to a sustained-release tramadol formulation for once daily oral administration, which, upon initial administration of one dose, provides an analgesic effect within 2 hours, which analgesic effect continues for at least 24 hours after administration.
Patent NZ-545982-A (NZ)
Title: Coated tablets comprising diclofenac in the core
Inventor: RAULT ISABELLE
IPC: A61K9/28
Filed: 2004-09-23
Abstract: Disclosed is a film coated tablet comprising a) a tablet core comprising diclofenac or a pharmaceutically acceptable salt thereof, and b) a coating comprising hydroxypropyl methylcellulose, stearic acid and microcrystalline cellulose.
Patent NZ-551082-A (NZ)
Title: Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
Inventor: O'CONNER OWEN A
IPC: A61K31/519
Filed: 2005-05-31
Abstract: Disclosed is the use of 10-propargyl-10-deazaaminopterin for treating T cell lymphoma.
Patent NZ-553229-A (NZ)
Title: Chimeric meningococcal NMB1870 polypeptide comprising fragments of NMB1870 polypeptides from a pluraity of different NMB1870 families
Inventor: MASIGNANI VEGA
IPC: A61K39/00
Filed: 2005-09-01
Abstract: Disclosed is a chimeric NMB1870 polypeptide comprising fragments of NMB1870 polypeptides from a plurality of different NMB1870 families and comprising the amino acid sequence (F-X)n, wherein: n is an integer between 2 and 10; each F is a fragment of at least 7 amino acids in length from an NMB1870 polypeptide subject to at least two of said F in the chimeric NMB1870 polypeptide being from different NMB1870 families; and each X is an optional amino acid sequence; subject to the proviso that said chimeric polypeptide does not have the same sequence as a full-length NMB1870 polypeptide of family I, family II or family III from Neisseria meningitidis strain MC58, 961, 5945 or 2996 or a full-length NMB1870 amino acid sequence of family I, family II or family III from Neisseria meningitidis strain MC58, 961, 5945 or 2996 having a truncation in the N-terminus sequence up to and including a poly-glycine region thereof. Further disclosed are nucleic acids encoding said polypeptide, compositions comprising said polypeptide, processes for producing said polypeptide and uses thereof.
Patent NZ-553412-A (NZ)
Title: Barb configurations for barbed sutures
Inventor: LEUNG JEFFERY C
IPC: A61B17/06
Filed: 2003-09-29
Abstract: A barbed suture for connecting human or animal tissue, the suture comprising (a) an elongated body having a first end and a second end and a diameter and (b) a plurality of barbs projecting from the body, each barb facing in a direction and being adapted for resisting movement of the suture, when in tissue, in an opposite direction from the direction in which the barb faces, wherein the barbs have a configuration comprising a barb cut length with a ratio of the barb cut length to the suture diameter ranging from about 0.2 to about 2.
Patent NZ-555029-A (NZ)
Title: Movable Joint Having Up To Six Degrees Of Freedom
Inventor: MALONEY GEOFF
IPC: A61F5/01
Filed: 2005-11-18
Abstract: A movable joint (100) including: a body (102) having two spaced apertures (104, 106) connected by an opening (108); two arms (110, 112) having ends receivable in the apertures; and a resilient connector (114) passing though the opening (108) to connect the ends of the arms in the apertures, wherein the resilience of the resilient connector: allows independent movement of the arms in up to six degrees of freedom which is controlled by engagement of abutment portions (120) of the arms (110, 112) with respective abutment portions (122) of the apertures (104, 106); and absorbs force applied to the arms.
Patent NZ-564376-A (NZ)
Title: Method for the synthesis of anthocyanins
Inventor: BAKSTAD EINAR
IPC: C07H15/18
Filed: 2006-06-15
Abstract: Disclosed is a method for preparing an Eastern portion of anthocyanin comprising reacting an alpha functionalised ketone starting material of general formula S-1, with a sugar anion of general formula XO-. Also disclosed is the compound of formula S-1, wherein LG is Br or I and R1, R2 and R3 each denote a benzyloxy, or R1 denotes H and R2 and R3 together denote diphenylmethylenedioxy. Also disclosed are compounds of formula (i), (ii) or (iii).
Patent NZ-569044-A (NZ)
Title: Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
Inventor: REITZ ALLEN B
IPC: A61K31/353
Filed: 2006-12-19
Abstract: Disclosed is the use of benzo-fused heterocycle sulfamide compounds of formula (I), wherein the substituents are as defined in the specification, and their use in treating alcohol abuse or addiction.
Patent NZ-569811-A (NZ)
Title: Connected labels which are separable from each other each formed by an elastic loop attached to a tag
Inventor: LUDLOW ROBERT B
IPC: G09F3/14
Filed: 2006-01-17
Abstract: A linear series (110) of connected unitary sheet-like merchandise labels (10) is disclosed. Each label (10) it formed from a labelling tag (12) flatly co-joined along a unifying flat bond zone (14) with a flexible elastic layer (16) that extends away from the tag (12) and includes an elastic fastening loop (20). Adjacent label (10) of the series (110) are connected in a manner permitting the series (110) to be handled as a unit while at the same time permitting separation of individual labels (10) from the series (110). In one embodiment, the linear series (110) is wound into roll form.
Patent NZ-572549-A (NZ)
Title: Pyrrolopyrimidine compounds and their uses
Inventor: BRAIN CHRISTOPHER THOMAS
IPC: A61K31/522
Filed: 2007-05-24
Abstract: Disclosed are 7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid amides of Formula I or a pharmaceutically acceptable salt or solvate thereof, wherein: the dashed line indicates a double bond; A is N; R2 and R3 are each, independently, selected from the group consisting of hydrogen, hydroxyl, alkyl, cycloalkyl, heterocyclyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; R4 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, cycloalkyl, aryl and heteroaryl; X is CR11, and Y is CR12; R11 is hydrogen, or alkyl and R12 is BC(O)NR13R14; wherein B is a bond or alkyl; wherein R13 and R14 are each, independently, selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl for the treatment of cancer wherein the cancer is selected from the group consisting of bladder, head and neck, breast, stomach, ovary, colon, lung, brain, larynx, lymphatic system, genitourinary tract, gastrointestinal, ovarian, prostate, gastric, bone, smallcell lung, glioma, colorectal and pancreatic cancer.
Patent NZ-575075-A (NZ)
Title: Method for removing diseased cells from non-diseased cells
Inventor: REED THOMAS D
IPC: C12N5/00
Filed: 2007-07-26
Abstract: An in vitro method for obtaining live, non-diseased cells for treating a disease by destroying diseased cells from a subject. The method comprises: a. Determining the activity of at least one disease marker gene within a population of cells obtained from a subject; b. Introducing into the cells a polynucleotide that encodes a selectable marker and a polypeptide that is lethal to the cell, wherein the expression of the lethal polypeptide is directly or indirectly controlled by the promoter of the disease marker gene; c. Exposing the cells to selection conditions to obtain cells that comprise the polynucleotide; d. Treating the cells with conditions to induce expression of the lethal polypeptide to kill the cells expressing the disease marker gene; and e. Separating the dead cells from the remaining live, non-diseased cells, wherein the live cells do not express the lethal polypeptide to an extent sufficient to kill the non-diseased cells. The cells can be a population of stem cells and the disease marker gene can be a cancer gene.
Patent NZ-575484-A (NZ)
Title: Electrolysis cell with vertical current outlet with taper
Inventor: OVSTETUN FRANK
IPC: C25C3/06
Filed: 2007-09-12
Abstract: Disclosed is an electrolysis cell (1) with electrical current distribution using vertical outlets. The cell comprises a substantially horizontal cathode structure (4) and a bus bar system, the cathode structure being of an electronic conducting material having integrated current leads such as horizontal collector bars embedded therein. The cathode structure comprises at least one substantial vertical electrical current outlet (6, 6') connected to the bus bar system, with the outlet having a downwardly tapered section. The outlet is further provided with at least one horizontal current lead portion that is embedded in the cathode material and in electrical contact with same
Patent NZ-577937-A (NZ)
Title: Combination product for controlling parasites on animals
Inventor: SIRINYAN KIRKOR
IPC: A01N25/02
Filed: 2007-12-14
Abstract: Disclosed is a composition for controlling parasites on animals, which comprises an N-arylpyrazole (such as fipronil or 5-amino-4-trifluoromethylsulphinyl-1-(2,6-dichloro-4-trifluoromethylphenyl)-3-thiocarbamoylpyrazole) and a pyrethroid (such as flumethrin or permethrin) in a formulation comprising: an aliphatic cyclic carbonate selected from ethylene carbonate or propylene carbonate and mixtures thereof; an aliphatic cyclic or acyclic polyether being an ether derived from a diol having up to 8 carbon atoms (such as diethylene glycol monoethyl ether, diethylene glycol monopropyl ether or dipropylene glycol monopropyl ether), or a 5- or 6-membered cyclic ether having a ring oxygen and 4 or 5 ring carbon atoms and optionally carrying a alkyl substituent (such as tetrahydrofurfuryl alcohol); and one or more esters of a dihydric or trihydric alcohol having up to three carbon atoms with organic fatty acids having 6 to 18 carbon atoms.
Patent NZ-578248-A (NZ)
Title: Seamless sock made by alternate motion stitching
Inventor: BUSI MAURO
IPC: G06F15/173
Filed: 2007-11-26
Abstract: A method for making, through a circular machine for making socks with alternate motion, an item of clothing like an ankle sock (10) in 'continuum' stitched without seams to form a single piece made up of a front end (100) elongated in the shape of a pocket, that can be associated with the toe of the foot and comprising a first and a second front portion (11, 12), a rear end (200), also pocket-shaped, able to be associated with the heel of the foot and comprising a first and a second rear portion (21, 22), and a connecting part (300) between the front and rear ends, comprising a sole portion (31) and two side portions (32), having an opening in which to insert the foot.
Patent NZ-587408-A (NZ)
Title: Method of producing a cereal bran product containing beta-glucan
Inventor: LEHTOMAKI ILKKA
IPC: A23L7/104
Filed: 2009-03-04
Abstract: A method of manufacturing a cereal bran product containing beta-glucan. The method consists of the following stages: (a) the cereal bran is pre-treated by fine grinding or extrusion, whereby the beta-glucan is brought out of the cereal bran; (b) the cereal bran is thermo-mechanically treated in an extrusion or expansion process, whereby a plastic mass is formed from the cereal bran; (c) the mass is brought into contact with an enzyme that breaks up beta-glucan and optionally with another enzyme that breaks up starch; (d) the enzymes are inactivated; and (e) the bran is dried and optionally ground. Cereal bran that can be used in the method can be the grains from oat, barley or rye. The enzyme that breaks up beta-glucan can be beta-glucanase and the enzyme that breaks up starch can be alpha-amylase.
Patent NZ-587955-A (NZ)
Title: Boron-containing small molecules as anti-inflammatory agents
Inventor: AKAMA TSUTOMU
IPC: A61K31/69
Filed: 2009-03-05
Abstract: Disclosed are boron-containing small molecule compounds represented by the structural formula shown herein and methods of treating anti-inflammatory conditions. In an exemplary embodiment, the compounds represented by said structural formula include 5-(4-Cyanophenoxy)-1-hydroxy-2,1-benzoxaborole; 1,3-Dihydro-1-hydroxy-5-phenoxy-2,1-benzoxaborole; 5-[4-(N,N-Diethylcarbamoyl)phenoxy]-1,3-dihydro-1-hydroxy-2,1-benzoxaborole and numerous similar compounds disclosed in the specification. These compounds are useful for treating conditions selected from arthritis, rheumatoid arthritis, an inflammatory bowel disease, psoriasis, a pulmonary disease, multiple sclerosis, a neurodegenerative disorder, congestive heart failure, stroke, aortic valve stenosis, kidney failure, lupus, pancreatitis, allergy, fibrosis, anemia, atherosclerosis, a metabolic disease, a bone disease, a cardiovascular disease, a chemotherapy/radiation related complication, diabetes type I, diabetes type II, a liver disease, a gastrointestinal disorder, an ophthamological disease, allergic conjunctivitis, diabetic retinopathy, Sjogren's syndrome, uvetitis, a pulmonary disorder, a renal disease, dermatitis, HIV-related cachexia, cerebral malaria, ankylosing spondolytis, leprosy, anemia and fibromyalgia.